The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.
Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...
Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisParis, December 24, 2025.
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...
Sanofi (SNY) announced on Wednesday that the U.S. FDA issued a complete response letter regarding its marketing application ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
Two recent studies presented at the 4th Congress of the European Academy of Neurology examined the different effects and aspects of progressive multiple sclerosis. Two recent studies presented at the ...
Peter L. Salgo, MD: I feel your pain, with just 1 diagnosis code. You’re relying on clinicians to speak to this. And is there a generalized agreement? Do all payers, and all providers, follow common ...
At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...
Secondary progressive multiple sclerosis (SPMS) is a form of MS that typically follows relapsing-remitting MS (RRMS). It is characterized by steady accumulation of disability without relapses. About ...
September 17, 2009 (Düsseldorf, Germany) — The largest controlled study of an agent in secondary progressive multiple sclerosis has shown that dirucotide has no significant treatment effect in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback